Cencora, Inc. $COR is Carmignac Gestion’s 5th Largest Position

Carmignac Gestion grew its position in shares of Cencora, Inc. (NYSE:COR) by 25.8% in the 1st quarter, HoldingsChannel.com reports. The fund owned 1,101,251 shares of the company’s stock after acquiring an additional 226,156 shares during the period. Cencora comprises about 5.3% of Carmignac Gestion’s holdings, making the stock its 5th largest position. Carmignac Gestion’s holdings in Cencora were worth $345,930,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Kemnay Advisory Services Inc. acquired a new position in shares of Cencora in the 4th quarter valued at about $25,000. Oakworth Capital Inc. acquired a new stake in Cencora during the 4th quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new stake in Cencora during the 4th quarter worth approximately $27,000. Archer Investment Corp raised its holdings in Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after buying an additional 47 shares during the period. Finally, Motiv8 Investments LLC purchased a new position in Cencora in the fourth quarter valued at approximately $29,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Performance

Cencora stock opened at $312.40 on Monday. The firm has a market capitalization of $60.78 billion, a PE ratio of 23.96, a price-to-earnings-growth ratio of 1.73 and a beta of 0.57. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The stock’s 50 day moving average price is $289.36 and its 200 day moving average price is $315.41. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s revenue was up 3.9% compared to the same quarter last year. During the same period last year, the business earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts expect that Cencora, Inc. will post 17.8 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s dividend payout ratio is 18.40%.

Cencora declared that its board has authorized a share repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

COR has been the topic of a number of recent research reports. UBS Group lifted their price target on shares of Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Wells Fargo & Company dropped their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Weiss Ratings downgraded shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 30th. Barclays reduced their target price on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Finally, Robert W. Baird decreased their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus target price of $367.75.

Insider Buying and Selling at Cencora

In other news, Director Lauren M. Tyler purchased 550 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was acquired at an average cost of $270.23 per share, with a total value of $148,626.50. Following the acquisition, the director owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.38% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.